Q4 2025 Neogenomics Inc Earnings Call Transcript
Key Points
- NeoGenomics Inc (NEO) reported record revenues for the fourth quarter of 2025, with total revenue reaching $190 million, representing an 11% year-over-year growth.
- The company's clinical business showed robust growth, with revenue increasing by 16% year-over-year, driven by effective execution of key commercial strategies.
- NeoGenomics Inc (NEO) achieved a net promoter score of 79, indicating strong physician satisfaction and improved customer loyalty.
- The company successfully launched five NGS products since 2023, contributing significantly to clinical revenue and demonstrating strong market uptake.
- NeoGenomics Inc (NEO) is expanding its sales force to penetrate the head and neck cancer market, aiming to capitalize on its unique Moldex-approved HPV negative test.
- Non-clinical revenue declined by over 25% in the fourth quarter, impacting overall revenue growth.
- The company is experiencing a shift in growth dynamics, with a focus on higher AUP rather than volume, which may affect short-term revenue growth.
- NeoGenomics Inc (NEO) anticipates continued modest erosion in its pharma business, with a return to growth not expected until 2027.
- The company faces challenges in securing timely Moldex approvals for new product launches, which could delay revenue contributions.
- Extreme weather conditions have impacted provider operations, potentially affecting first-quarter volumes and revenue.
Good morning and welcome to the Neogenomics 4th quarter and full year 2025 financial results call. Please be advised that today's conference is being recorded. I will now turn the call over to Kendra Webster with Neogenomics. The floor is yours.
Thank you, Kelly, and good morning everyone. Welcome to the Neogenomics 4th quarter in full year 2025 financial results call. With me today to discuss the results are Tony Zu, Chief Executive Officer, Jeff Sherman, Chief Financial Officer, and Abhishek Jain, EVP of Finance. Additional members of the management team will be available for the Q&A portion of our call. This call is being simultaneously webcast for reference concurrent with today's call, we posted a short slide presentation to the investors tab on our website at ir.neogenomics.com.
During this call, we will make forward-looking statements regarding our future financial and business performance, business strategy, the timing and outcome of reimbursement decisions, and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
